Riskpilot← Back to searchSign inGet full accessOMET Pharma AB
ABActiveOrg 5592533805Tippvägen 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20200 employees
Revenue 2024
SEK 13,9M
+116% vs 2023
EBITDA margin
1.8%
-60% vs 2023
Equity ratio
5.4%
Financial strength
Net profit 2024
SEK -5K
-101% vs 2023
| Revenue | SEK 13,9M | +116% |
| EBITDA | SEK 245K | -60% |
| Net profit | SEK -5K | -101% |
| Total assets | SEK 10,7M | +54% |
| Equity | SEK 570K | -1% |
| Employees | 0 | — |
Legal name
OMET Pharma AB
Org number
5592533805
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23 april 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Partihandel av läkemedel.
Address
Tippvägen 2
Email
jungbeck@ometpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 2 102 | 4 209 | 6 418 | 13 882 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −440 | 500 | −356 | 614 | 245 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −440 | 500 | −356 | 614 | 245 |
| Net financials | — | −45 | −95 | −132 | −244 |
| Profit before tax | −440 | 455 | −451 | 482 | 1 |
| Tax | −0 | −3 | −0 | −7 | −6 |
| Net profit | −440 | 452 | −451 | 475 | −5 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 148 | 2 797 | 6 190 | 6 926 | 10 654 |
| Equity | 99 | 551 | 100 | 575 | 570 |
| Long-term debt | 0 | 2 188 | 5 023 | 3 606 | 3 761 |
| Short-term debt | 48 | 58 | 1 067 | 2 745 | 6 323 |
| Total debt | 48 | 2 246 | 6 090 | 6 351 | 10 084 |
EBITDA margin
1.8%
This company
15.8%
Market median
-89% vs market
20202024
Equity ratio
5.4%
This company
38.2%
Market median
-86% vs market
20202024
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20202024
Net profit margin
-0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
1.30×
This company
1.12×
Market median
+16% vs market
20202024
Debt / equity
17.68×
This company
0.62×
Market median
-2752% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2020 | |
| Deputy Board Member | 2025 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OMET Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Petar Karlovic Bast | Chairman | 0 companies |
| Jan Erik Anders Jungbeck | Board of Directors | 0 companies |
| Mats Bo Ingmar Wilson | Deputy Board Member | 0 companies |
| Inge Dan Marcus Johansson | Deputy Board Member | 0 companies |